Feature Channels: Clinical Trials

• share
• favorite_border

• share
• favorite_border

Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children’s Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma.

• share
• favorite_border

In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in significant improvements in fatigue. Researchers say the findings could shape treatment approaches to one of the most challenging symptoms experienced by people with multiple sclerosis.

• share
• favorite_border

• share
• favorite_border

Inflammation of the arteries is a primary precursor and driver of cardiovascular disease — the No. 1 killer of people in the United States. This inflammation is associated with the buildup of dangerous plaque inside the arteries. Advanced treatments are needed to target this inflammation in patients. Michigan State University researchers have tested a new nanoparticle nanotherapy infusion that precisely targets inflammation and activates the immune system to help clear out arterial plaque.

• share
• favorite_border

A new systematic review led by researchers in Hamilton, Canada has shown that specialized in-bed cycling therapy, when used in the intensive care unit with critically ill patients, leads to better physical function and a one-day shorter length of stay in the ICU.

• share
• favorite_border

For the fifth year in a row, Dr. Adrien Eshraghi and Dr. Ronna Hertzano lectured on the year’s most important hearing loss research at the annual AAO-HNSF meeting.

• share
• favorite_border

Research by James LaBelle shows how a widely used cancer drug has broader effects on the immune system.

• share
• favorite_border

A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.

• share
• favorite_border

UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the treatment of early symptomatic Alzheimer’s disease.

• share
• favorite_border

Houston Methodist researchers have developed an advanced mathematical model that predicts how novel treatment combinations could significantly extend progression-free survival for patients with non-small-cell lung cancer (NSCLC), the most common type of lung cancer.

• share
• favorite_border

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

• share
• favorite_border

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana’s main ingredient, THC, reduces agitation in patients with Alzheimer’s by an average of 30%.

• share
• favorite_border

Recent results from one of the I-SPY 2.2 study arms, published September 14, 2024 in Nature Medicine, showed that neoadjuvant treatment with the antibody-drug conjugate datopotamab–deruxtecan (Dato-DXd) in combination with the immune checkpoint inhibitor, durvalumab (Imfinzi), produced high rates of pCR in patients who have an immune breast cancer subtype as well as a subtype of triple negative cancer that would ordinarily have a high risk of recurrence.

• share
• favorite_border

Researchers from the UChicago Medicine Comprehensive Cancer Center published results from a clinical trial evaluating a novel combination treatment for advanced bladder cancer.

• share
• favorite_border

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

Largest Global Gathering of Kidney Professionals Expands Program to Include More Breaking Research and Focused Discussions on Key Public Health and Policy Issues

• share
• favorite_border

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.